Lymphoma Clinical Trial
Official title:
A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors
Verified date | February 2013 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as temozolomide, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving bortezomib together with
temozolomide may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when
given together with temozolomide in treating patients with brain tumors or other solid
tumors that have not responded to treatment.
Status | Completed |
Enrollment | 25 |
Est. completion date | January 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed solid tumors including the following - Recurrent high-grade glioma - Recurrent metastatic brain tumors - Recurrent primary brain tumor including primary CNS lymphoma - Other refractory solid tumors - Unresectable disease for which standard curative or palliative measures do not exist or are no longer effective - Measurable or nonmeasurable disease PATIENT CHARACTERISTICS: Inclusion criteria: - Karnofsky performance status 60-100% - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Serum creatinine = 1.5 x upper limit of normal (ULN) - Total bilirubin = 2.0 mg/dL - AST = 4.0 x ULN - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Patient must be able to understand and is willing to sign a written informed consent document Exclusion criteria: - Any of the following conditions: - Myocardial infarction within the past 6 months or New York Heart Association class III or IV heart failure - Uncontrolled angina - Severe uncontrolled ventricular arrhythmias - ECG evidence of acute ischemia or active conduction system abnormalities - Any ECG abnormalities prior to study entry must be documented by the investigator as not medically relevant - Serious medical or psychiatric illness that would, in the opinion of the investigator, potentially interfere with the completion of treatment - History of sensitivity to boron or mannitol PRIOR CONCURRENT THERAPY: Inclusion criteria: - At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea-containing chemotherapy), immunotherapy, or radiotherapy and recovered - More than 10 days since prior anticonvulsant drugs that induce hepatic metabolic enzymes for patients in group A - Recovered from major surgery - Corticosteroids for cerebral edema allowed provided the patient is on a stable dose for at least 1 week Exclusion criteria: - Patients enrolled on another clinical trial - HIV-positive patients on antiretroviral therapy - Concurrent chemotherapy or radiotherapy - Patient requires anti-seizure medication but is not on a stable dose and agent of anti-seizure medication |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | City of Hope Medical Group | Pasadena | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting toxicity and maximum tolerated dose | 28 days | Yes | |
Secondary | Pharmacokinetics | Day 9 | No | |
Secondary | Confirmed complete or partial response | 6 months | No | |
Secondary | Percentage of patients with 6-month progression-free survival | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |